Get the app!
Back to Trades
Sell4

Denali Therapeutics Inc.

DNLI

Total Value
$51.7K
Net $51.7K sold
Sales
$51.7K
2 transactions

Company Information

Ticker Symbol
DNLI
CIK
0001714899

Insider Information

Role
Chief Medical Officer
Officer
Location
SOUTH SAN FRANCISCO, CA

Filing Details

Filing Date
Aug 14, 2025
Transaction Date
Aug 12, 2025
Accession Number
0001714899-25-000176
Form Type
4
Net Trading Amount
-$51.7K

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Aug 12, 2025Common Stock2,937$13.58Sale$39.9K
Aug 13, 2025Common Stock806$14.64Sale$11.8K

Footnotes

  1. (F1)Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
  2. (F2)The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. (F3)Includes 128,405 Unvested RSUs.
  4. (F4)The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
  5. (F5)The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
  6. (F6)The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.